Letters sent to hospital chiefs and cancer research leaders by NHS England suggesting funding for care of patients taking part in drug trials might be cut were incorrect it has said  The letter sent to health bosses in London blamed the financial climate NHS England has now overruled the letter which was obtained by Labour and seen by the BBC It says it will be writing to area teams to clarify Cancer Research UK said the NHS had to keep its side of the bargain Excess treatment costs ETCs cover the care of patients involved in drug trials which are not already covered by the pharmaceutical or academic research body involved   Traditionally the NHS has covered these costs for patients who wish to take part in the trials The letter from the head of specialised commissioning at NHS England London Region dated  November was written to hospital trust medical directors and leaders in the field of cancer research It said I am sure you will appreciate that in the current financial climate the primary call for resources is to support clinical service provision for established service priorities  To this end the NHS England London Region Area Team is unable to identify any uncommitted resources which could be used to support ETCs for clinical trials This is the national position which is being adopted in respect of all current requests for ETCs Andy Burnham Labours shadow health secretary called the withdrawal of the letter a Uturn He added This was announced as a new national policy to be rolled out and we are not convinced that this is simply an inaccurate letter Health Secretary Jeremy Hunt must make a full statement to clarify what has happened Mr Burnham said the letter indicates the growing financial crisis in the NHS Speaking to BBC Breakfast he said the episode had been shambolic and it was clear the health service needed more money Mr Burnham added that Labour had been criticised for pledging to introduce a mansion tax to help fund the NHS but said it would do it because the health service was the partys top priority Cancer Research UK which is currently supporting drug trials involving about  patients said it had concerns   Prof Peter Johnson Cancer Research UKs chief clinician said The partnership between the NHS and organisations which fund research such as Cancer Research UK has been a great success story  We lead the world in being able to offer patients participation in clinical trials but all this will be undone if the NHS cannot keep its side of the bargain A spokesman for NHS England said We strongly support medical research and we will fund excess treatment costs in line with the national rules so these local letters were incorrect and are being withdrawn A Department of Health spokesman said Research in the NHS is vital and has this governments strong support We have asked NHS England to set out how they will deliver their objective to promote research and ensure the payment of excess treatment costs